Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules... Show more
a developer of therapeutic drugs
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TSUI | 23.81 | 0.89 | +3.89% |
| 21Shares Sui Staking ETF Common Shares of Beneficial Interest Shares (TSUI) | |||
| CLOD | 35.67 | 0.41 | +1.18% |
| Themes Cloud Computing ETF (CLOD) | |||
| PDP | 138.99 | 1.16 | +0.84% |
| Invesco Dorsey Wright Momentum ETF (PDP) | |||
| TMFG | 29.85 | -0.12 | -0.40% |
| Motley Fool Global Opportunities ETF (TMFG) | |||
| IBBQ | 34.42 | -0.72 | -2.05% |
| Invesco Nasdaq Biotechnology ETF (IBBQ) | |||
A.I.dvisor indicates that over the last year, ATHE has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHE jumps, then EYPT could also see price increases.
| Ticker / NAME | Correlation To ATHE | 1D Price Change % | ||
|---|---|---|---|---|
| ATHE | 100% | -2.49% | ||
| EYPT - ATHE | 54% Loosely correlated | -1.22% | ||
| SLDB - ATHE | 38% Loosely correlated | -3.46% | ||
| TECX - ATHE | 35% Loosely correlated | -2.66% | ||
| GHRS - ATHE | 31% Poorly correlated | -2.64% | ||
| IVVD - ATHE | 30% Poorly correlated | -6.16% | ||
More | ||||
ATHE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 48 cases where ATHE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ATHE's RSI Oscillator exited the oversold zone, 26 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 73 cases where ATHE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +12.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATHE advanced for three days, in 149 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATHE as a result. In 94 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ATHE turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ATHE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ATHE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.128) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATHE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.